Celcuity (NASDAQ:CELC) Upgraded by Wall Street Zen to “Hold” Rating

Celcuity (NASDAQ:CELC) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

CELC has been the topic of several other research reports. Leerink Partners increased their price objective on shares of Celcuity from $28.00 to $60.00 and gave the stock an “outperform” rating in a research note on Monday, July 28th. Stifel Nicolaus initiated coverage on shares of Celcuity in a research note on Tuesday, July 1st. They set a “buy” rating and a $30.00 target price on the stock. HC Wainwright raised their target price on shares of Celcuity from $50.00 to $66.00 and gave the stock a “buy” rating in a research note on Monday, August 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a research note on Wednesday, October 8th. Finally, Needham & Company LLC restated a “buy” rating and set a $70.00 target price on shares of Celcuity in a research note on Friday, October 3rd. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $56.50.

Celcuity Price Performance

Shares of NASDAQ:CELC opened at $51.96 on Friday. The firm’s 50 day moving average price is $51.77 and its 200-day moving average price is $27.43. Celcuity has a twelve month low of $7.57 and a twelve month high of $63.06. The company has a quick ratio of 4.58, a current ratio of 4.58 and a debt-to-equity ratio of 2.24. The stock has a market capitalization of $2.20 billion, a PE ratio of -15.06 and a beta of 0.70.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.14). Equities research analysts expect that Celcuity will post -2.62 EPS for the current year.

Insider Activity

In other news, Director David Dalvey sold 100,000 shares of Celcuity stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $43.98, for a total transaction of $4,398,000.00. Following the sale, the director owned 125,000 shares in the company, valued at $5,497,500. This trade represents a 44.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 15.77% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Celcuity

Institutional investors and hedge funds have recently modified their holdings of the stock. Trexquant Investment LP raised its position in shares of Celcuity by 131.3% during the first quarter. Trexquant Investment LP now owns 26,920 shares of the company’s stock valued at $272,000 after buying an additional 15,280 shares during the last quarter. Baker BROS. Advisors LP raised its position in shares of Celcuity by 59.0% during the first quarter. Baker BROS. Advisors LP now owns 4,257,735 shares of the company’s stock valued at $43,046,000 after buying an additional 1,579,182 shares during the last quarter. Rhumbline Advisers raised its position in shares of Celcuity by 8.9% during the first quarter. Rhumbline Advisers now owns 42,194 shares of the company’s stock valued at $427,000 after buying an additional 3,439 shares during the last quarter. Nuveen LLC purchased a new position in shares of Celcuity in the first quarter valued at $704,000. Finally, GAMMA Investing LLC grew its holdings in shares of Celcuity by 1,237.4% in the first quarter. GAMMA Investing LLC now owns 1,324 shares of the company’s stock valued at $131,000 after purchasing an additional 1,225 shares in the last quarter. Institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.